Form 8-K - Current report:
SEC Accession No. 0001213900-25-106723
Filing Date
2025-11-05
Accepted
2025-11-05 17:26:12
Documents
15
Period of Report
2025-11-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0264149-8k_moonlake.htm   iXBRL 8-K 31098
2 UNDERWRITING AGREEMENT, DATED NOVEMBER 5, 2025, BY AND BETWEEN MOONLAKE IMMUNOTH ea026414901ex1-1_moonlake.htm EX-1.1 240496
3 OPINION OF WALKERS (CAYMAN) LLP ea026414901ex5-1_moonlake.htm EX-5.1 43697
4 GRAPHIC ex5-1_001.jpg GRAPHIC 4755
  Complete submission text file 0001213900-25-106723.txt   557939

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE mltx-20251105.xsd EX-101.SCH 3020
6 XBRL LABEL FILE mltx-20251105_lab.xml EX-101.LAB 34239
7 XBRL PRESENTATION FILE mltx-20251105_pre.xml EX-101.PRE 22362
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0264149-8k_moonlake_htm.xml XML 3551
Mailing Address DORFSTRASSE 29 ZUG V8 6300
Business Address DORFSTRASSE 29 ZUG V8 6300 41 41 510 8022
MoonLake Immunotherapeutics (Filer) CIK: 0001821586 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39630 | Film No.: 251455241
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)